Significance of anti-phospholipase A2 receptor antibodies in membranous nephropathy after renal transplantation

Idiopathic membranous nephropathy and anti-phospholipase A2 receptor antibodies.

Phospholipase A2 receptor antibodies in membranous nephropathy: unresolved issues.

The discovery of theM-type phospholipase A2 receptor (PLA2R) as a major antigen in idiopathic membranous nephropathy (iMN) was a breakthrough and established iMN as an autoimmune disease.1 Subsequent studies confirmed that antibodies against PLA2R were present in approximately 70% of incident iMN patients (reviewed by Hofstra and Wetzels2). The potential role ofmeasuring PLA2R antibodies for cl...

Anti-phospholipase A2 receptor antibody in membranous nephropathy.

The M-type phospholipase A2 receptor (PLA2R) is a target autoantigen in adult idiopathic membranous nephropathy (MN), but the prevalence of autoantibodies against PLA2R is unknown among Chinese patients with MN. Here, we measured anti-PLA2R antibody in the serum of 60 patients with idiopathic MN, 20 with lupus-associated MN, 16 with hepatitis B (HBV)-associated MN, and 10 with tumor-associated ...

Anti-Phospholipase A2 Receptor Antibodies in Membranous Nephropathy: from Bench to the Patient

Membranous nephropathy (MN) is a glomerular disease histologically characterized by an uniform thickening of glomerular basement membranes (GBM) caused by subepithelial electrondense deposits of immune complexes, in which the antibody is an IgG. In about 2/3 of cases the etiology of MN is unknown and the disease is called primary or idiopathic. In the remaining cases MN may be secondary to syst...

Anti-phospholipase A2 Receptor Antibody and Immunosuppression in Membranous Nephropathy: More Evidence for Pathogenicity of Anti-phospholipase A2 Receptor Autoantibodies.

In the 6 years since the discovery of anti-phospholipase A2 receptor (anti-PLA2R) antibodies in the majority of patients with primary membranous nephropathy (MN),1 our understanding of the role of anti-PLA2R in clinical disease has evolved rapidly. The initial small retrospective clinical studies indicated that anti-PLA2R levels could be modulated by immunosuppression.1,2 Levels decreased in ad...